Yesterday, Pfizer released a strong earnings report (surpassing Wall Street’s elevated projections), and also revealed that it’s both on the cusp of securing regulatory approval in the US for minors between the ages of 12 and 15 to receive the vaccine (setting off another wave of demand as the Biden Administration heaps pressure on states to get their vaccination numbers up). During a call with analysts and reporters, CEO Albert Bourla revealed that Pfizer is in talks with “basically all the governments of the world” about providing shots and booster shots through 2024. ooking ahead, CNN reported Wednesday that the FDA will approve the Pfizer-BioNTech COVID jab for use in 12 to 15 year olds as early as next week. Data released by Pfizer recently purported to show that the jab is 100% effective at preventing serious symptoms. According to recent media reports, Pfizer is also seeking approval for the vaccine to be used on children as young as 2 and as old as 11 in both the US and Europe, an authorization it expects to arrive in September.
[dntplgn recurring_amt1=”4.50″ recurring_amt2=”3.00″ recurring_amt3=”1.50″ item_name=”Donation for EarthNewspaper.com” paypal_email=”email@example.com” currency_code=”USD” currency_symbol=”$” return_url=” https://earthnewspaper.com/index.php/thank-you-for-donating-to-earthnewspaper-com”]